Molecular Pharmaceutics · 2011 · 72 citations · 22 references
PharmacyBiotechnologyOphthalmologyGene DeliveryGene TherapyOcular DiseaseOcular Gene DeliveryOcular Gene TherapyOcular NanocarriersOcular Targeted DeliveryProtein DeliveryConjunctival MucinsGelatin BiomaterialsGelatin NanoparticlesNanomaterials For Ocular ApplicationsNanoparticle-based Ophthalmic FormulationsNanoparticle-loaded Ocular ImplantsOcular Surface TargetingTransfection Optimization
Decreased production of the mucin MUC5AC in the eye is related to several pathological conditions, including dry eye syndrome. A specific strategy for increasing the ocular levels of MUC5AC is not yet available. Using a plasmid specially designed to encode human MUC5AC, we evaluated the ability of hybrid cationized gelatin nanoparticles (NPs) containing polyanions (chondroitin sulfate or dextran sulfate) to transfect ocular epithelial cells. NPs were developed using the ionic gelation technique and characterized by a small size (<200 nm), positive zeta potential (+20/+30 mV), and high plasmid association efficiency (>95%). MUC5AC mRNA and protein were detected in conjunctival cells after in vitro transfection of the NPs. The in vivo administration of the NPs resulted in significantly higher MUC5AC expression in the conjunctiva compared to untreated control and naked plasmid. These results provide a proof-of-concept that these NPs are effective vehicles for gene therapy and candidates for restoring the MUC5AC concentration in the ocular surface.
22
Discordant Protein and mRNA Expression in Lung Adenocarcinomas
Guoan Chen, Tarek G. Gharib, Chiang-Ching Huang et al. · Molecular & Cellular Proteomics · 2002 · 948 citations · Full text
An SV40-immortalized human corneal epithelial cell line and its characterization.
Kaoru Araki‐Sasaki, Yuichi Ohashi, T Sasabe et al. · PubMed · 1995 · 738 citations